Improving stem cell mobilization strategies: future directions.
about
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myelomaAdditional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma patientsTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersMobilization of endogenous bone marrow derived endothelial progenitor cells and therapeutic potential of parathyroid hormone after ischemic stroke in miceRegulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.Acellular bone marrow extracts significantly enhance engraftment levels of human hematopoietic stem cells in mouse xeno-transplantation modelsMobilization studies in complement-deficient mice reveal that optimal AMD3100 mobilization of hematopoietic stem cells depends on complement cascade activation by AMD3100-stimulated granulocytes.PlerixaforHeparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells.European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche.Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experienceThe ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes.Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent.Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected.Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment.The role of complement in the trafficking of hematopoietic stem/progenitor cells.Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.The High Effect of Chemomobilization with High-Dose Etopside + Granulocyte-Colony Stimulating Factor in Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation: A Single Center Experience.Macrophages: Key regulators of steady-state and demand-adapted hematopoiesis.Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AMLOutcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF aloneHematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.Cyclophosphamide vs salvage chemotherapy plus G-CSF as chemo-mobilization in Asian patients undergoing autologous hematopoietic stem cell transplant.Plerixafor: a peripheral blood stem cell mobilizer.Innate immunity as orchestrator of stem cell mobilization.Mobilization of hematopoietic stem cells into the peripheral blood.Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.Novel strategies for blood stem cell mobilization: special focus on plerixafor.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Novel agents and approaches for stem cell mobilization in normal donors and patients.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.Stem cells: novel players in the treatment of erectile dysfunction.Embryonic development of hematopoietic stem cells: implications for clinical use.Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.
P2860
Q24186469-7774FE5E-771D-487C-B980-4BEA3A882F24Q24202384-250897F0-D26A-4F12-9B4E-D5FDDE8CD90DQ26851202-C5C23F5C-4731-4AE1-9210-9726A180435AQ27324791-FABDC29E-DD1A-4EB1-A8BB-3042A6425F78Q27692619-3DFB2BD7-4EB9-45F9-B46A-EA288FE72971Q28727639-C5B1AEF8-3758-4AE9-A2D4-82F69EB22D17Q33726179-629B929C-670F-4FAB-96FF-4BCA75DB51B5Q33885517-A9CA7A6B-DB7F-4187-A097-FA717BE7FDC1Q34105074-44F3F6FC-F497-4269-8701-B375B89031FFQ34194325-FEB8A3CA-C14C-4F2F-95BF-9C2B1183FD46Q34432943-E9087B0F-E087-415D-BEB7-F496BA2EAB3EQ34577717-BD3F4B18-E3DE-4AE5-BC35-25034A031E2FQ34762492-A108C009-65F7-4FA8-BBAB-E7B7D8B8A4EBQ35041174-AB98AF2E-0B19-4303-A15F-30D76968582AQ35544484-06B14C6D-BD3C-446C-B9AF-C24C4A9C8E4AQ35760079-65DEF56B-9EC5-4E0C-AAAB-60EAEBA34689Q36067243-B95A9392-E103-4238-9699-367D4EA6745BQ36110279-4633C536-282D-4FEE-9C05-57ACC39EE267Q36121171-F4117D5D-598D-4FF7-B1E5-502674CD06FFQ36445393-CC5AEED7-6766-4552-B30D-5BECB6F8333AQ36751217-7BE2DF62-276D-4D6B-963D-C53FE54A21EAQ36856679-281D0F0E-3A46-4133-A774-4D7D1FC8970AQ37173297-79ED84F1-B5B1-405A-937D-2881E18AFB0FQ37230855-F1B6A015-5C10-4F36-9340-B84545EE3228Q37429206-F27826B2-FCC1-49D4-98DD-B912CEFEF102Q37429248-62185A30-A4A2-4669-893F-C5BBB542B287Q37605108-7A7C895C-9BE0-4516-9E60-6D2E78383CB0Q37625513-E857F881-A260-4E0D-8D2C-B91B38741C59Q37735840-23C4CD8F-85AC-49AA-AD2D-EE96AD7C117DQ37779488-5A11A617-A857-42EA-9F06-492D1C00D4C7Q37810088-FD0FE6CF-4FE8-41C6-97E6-31BB7FA57941Q37827058-69DB583F-4C3A-423A-8A09-2DE785AEDFDFQ37909447-00616395-59A2-4A21-9115-13441383AEB4Q37921284-E6E8022D-925C-46EB-8CBC-60665D6760D3Q37923309-C9056010-A4A8-4B28-AE73-58C73A245B2BQ37943423-886CD800-C65A-4132-82E1-D611E2A81A00Q37946242-96869483-08E0-4B28-A43A-A3A89A6E8DDDQ38010726-16825827-F61B-43E4-AAA1-16F48E19097DQ38193590-BF5C2FA1-7CD4-42ED-A230-9D9212377E38Q38199707-5523C095-0BC9-4FB7-9960-2B3D321F2D08
P2860
Improving stem cell mobilization strategies: future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improving stem cell mobilization strategies: future directions.
@en
Improving stem cell mobilization strategies: future directions.
@nl
type
label
Improving stem cell mobilization strategies: future directions.
@en
Improving stem cell mobilization strategies: future directions.
@nl
prefLabel
Improving stem cell mobilization strategies: future directions.
@en
Improving stem cell mobilization strategies: future directions.
@nl
P2093
P2860
P356
P1476
Improving stem cell mobilization strategies: future directions.
@en
P2093
J F DiPersio
J M McCarty
W Bensinger
P2860
P2888
P304
P356
10.1038/BMT.2008.410
P407
P577
2009-01-12T00:00:00Z